Effects of hydrogen-rich water on blood uric acid in patients with hyperuricemia: A randomized placebo-controlled trial.
Fenglin Wu, Jun Ma, Junli Xue, Xue Jiang, Jinyu Liu, Jiashuo Zhang, Yazhuo Xue, Boyan Liu, Shucun Qin · Heliyon · 2024
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In 4 patients with different doses (low and high doses) and duration (4 and 8 weeks) in patients with hyperuricemia, following an 8-week period, the High-HRW group exhibited a significant reduction in blood uric acid levels compared to the baseline (488.2 ± 54.1 μmol/L to 446.8 ± 57.1 μmol/L, P < 0.05). These findings add human evidence supporting molecular hydrogen's therapeutic potential to influence inflammatory regulation.
What the Findings Mean
H2HUBB reviewed how hydrogen-rich water affected the outcomes measured in 4 patients with different doses (low and high doses) and duration (4 and 8 weeks) in patients with hyperuricemia. Following an 8-week period, the High-HRW group exhibited a significant reduction in blood uric acid levels compared to the baseline (488.2 ± 54.1 μmol/L to 446.8 ± 57.1 μmol/L, P < 0.05).
What the Researchers Studied
The researchers studied 4 patients with different doses (low and high doses) and duration (4 and 8 weeks) in patients with hyperuricemia. The study used a placebo-controlled human clinical trial. The comparison condition was placebo.
What Effects Did Molecular Hydrogen Have?
4.66 mg/L H₂; approximately 1.54 mg H₂ ingested per reported dose (330 mL hydrogen-rich water); reported treatment duration: 8 weeks. Following an 8-week period, the High-HRW group exhibited a significant reduction in blood uric acid levels compared to the baseline (488.2 ± 54.1 μmol/L to 446.8 ± 57.1 μmol/L, P < 0.05). The authors concluded that as a rather safe agent, the prolonged consumption of HRW may be feasible in the management of hyperuricemia. Consumption of hydrogen-rich water (HRW) has been shown to have anti-inflammatory and metabolic-modulatory benefits.
Why These Findings Matter
These findings add human evidence supporting molecular hydrogen's therapeutic potential to influence inflammatory regulation and contribute to the growing body of molecular-hydrogen research.
How Strong Is This Evidence?
This is human clinical evidence from a placebo-controlled human clinical trial. H2HUBB interprets the findings in the context of the study design, sample, comparator, and measured outcomes rather than using one publication as a verdict on hydrogen therapy.
Technical Study Details
H2HUBB classifies this publication as human clinical study with human clinical evidence. The research population or model was 4 patients with different doses (low and high doses) and duration (4 and 8 weeks) in patients with hyperuricemia. The reported sample size was 100. The study used a placebo-controlled human clinical trial. The hydrogen delivery method was hydrogen-rich water. The reported hydrogen concentration was 4.66 mg/L H₂. H2HUBB translates the reported hydrogen dose as approximately 1.54 mg H₂ ingested per reported dose (330 mL hydrogen-rich water). The reported treatment duration was 8 weeks.
Limitations and Safety
No separate limitations or safety findings were identified in the source text available to H2HUBB.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.